// App-Quantinova.ai

TPS8127 : Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL).

Researchers

Presenter

  • Bartomeu Massuti

Principal Investigators

  • Delvys Rodriguez Abreu

  • Maria Sanchez Ronco

  • Ana Verdu

  • Miguel Angel Molina-Vila

  • Clara Mayo-de las Casas

  • Eva Pereira

  • Rosana Cajal

  • Maria Carmen Gonzalez-Arenas

  • Enric Carcereny

  • Rafael Rosell

  • Elisa Galvez

  • Jose Antonio Ortega

  • Francisco Aparisi

  • Noemi Reguart

  • Mara ngeles Sala

  • Dolores Isla

  • Jordi Remon

  • Margarita Majem

Medical Centers

  • Hospital Virgen de los Lirios, Alcoy, Spain

  • Spanish Lung Cancer Group Office, Barcelona, Spain

  • Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain

  • Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Pangaea Biotech, Cancer Therapeutics Innovation Group, USP Institut Universitari Dexeus, Barcelona, Spain

  • Hospital Insular de Gran Canaria, Gran Canaria, Spain

  • Pangaea Biotech, Laboratory of Translational Oncology, Barcelona, Spain

  • Hospital de Mataro, Mataro, SpainComplejo Hospitalario Universitario A Coruna, A Coruna, SpainMedical Oncology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain

  • Hospital General de Elche, Alicante, Spain

  • AstraZeneca, Madrid, Spain

  • University Hospital of Basurto, Bilbao, Spain

  • Alcala de Henares University, Madrid, Spain

  • Hospital General de Elda, Elda, Spain

  • Department of Pathology, Hospital Clinic de Barcelona, Barcelona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Gastric Cancer

  • Small cell lung cancer

  • Colorectal Cancer

  • Lung Cancer

Biomarkers

  • BCL2 like 11

  • Breast cancer type 1 susceptibility protein

  • Carboxypeptidase B1

  • Circulating tumor cells

  • Serine/threonine-protein kinase mTOR

  • Threonine at amino acid position 790

Drug/Treatment

  • Capecitabine + Oxaliplatin

  • Bevacizumab

  • Carboplatin

  • Oxaliplatin

  • Paclitaxel

  • Erlotinib hydrochloride

  • gefitinib

  • Olaparib

Outcome

  • Unknown

Study Design

  • randomized

  • superiority

Phase

  • II

Study Id's

  • NCT=1513174

Sponsors

  • AstraZeneca.

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved